MYELODYSPLASTIC SYNDROMES (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROMES (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Supercharged immune cells take on hard-to-treat blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard therapy. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from a dono…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:59 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a personalized cell therapy called CART123 in 18 adults with certain blood cancers (like acute myeloid leukemia) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
Blood disorder drug luspatercept under Long-Term safety review
Disease control Recruiting nowThis study looks at the long-term safety of luspatercept in people with certain blood disorders (MDS, beta-thalassemia, or myelofibrosis) who were already in a luspatercept trial. Participants either continue treatment or enter long-term follow-up to monitor side effects, disease…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New hope for rare bone marrow cancer: targeted pill takes on standard chemo
Disease control Recruiting nowThis study tests a daily pill (ivosidenib) against a standard chemotherapy (azacitidine) in adults with a bone marrow disorder called MDS that has a specific IDH1 gene mutation. About 48 people who have not had prior treatment with similar drugs will be randomly assigned to one o…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New cord blood transplant method aims to beat High-Risk blood cancers
Disease control Recruiting nowThis study tests an improved method for cord blood transplants in adults with hard-to-treat blood cancers like leukemia and lymphoma. The approach uses a standard set of steps—including chemotherapy, radiation, and careful follow-up—to help the body accept the new stem cells. Res…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:53 UTC
-
New drug cocktail aims to prevent deadly transplant complications in blood cancer patients
Disease control Recruiting nowThis study tests a new combination of drugs (bendamustine and cyclophosphamide) to prevent graft-versus-host disease and a dangerous immune reaction after a stem cell transplant. It includes 60 adults with high-risk blood cancers like acute myeloid leukemia or myelodysplastic syn…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New hope for blood cancer patients? early trial combines two drugs
Disease control Recruiting nowThis early-stage study tests a new drug (ICP-248) combined with a standard drug (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The main goals are to check safety, find the best dose, and see if the combo helps control the cancer. About 266 adult…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
New drug may help High-Risk patients get Life-Saving stem cell transplants
Disease control Recruiting nowThis study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 18, 2026 12:09 UTC